alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.21


 


 





UNITS #4 AND #5


SUB-LEASE AMENDMENT
NO. 3


 


 


Amendment
of Sub-Lease


 


Pursuant
to Section 47 of the Standard Industrial/Commercial Single-Tenant Sub Lease between the Port Hueneme Surplus Property Authority
and Stellar Biotechnologies, Inc. commencing November 1, 2000, the Lessor and Lessee hereby modify the beginning of Paragraph
58 of said Sub-Lease to read as follows:


 


"58.
Option to extend. Lessor hereby grants to Lessee the option to extend the Term of this Lease for three (3) additional five (5)
year option periods commencing November 1, 2015, for the first option, November 1, 2020, for the second option , and November
1, 2025, for the third option subject to each and all of the following terms and conditions: ...."


 


For
the twelve month period of time commencing November 1, 2015, Lessee and Lessor hereby agree that the new Base Rent under the Sub-Lease
shall be $0.20 per square foot of land. Accordingly, Paragraph 60 of said Sublease is hereby amended and replaced by the following:


 


"
60. Establishment of Base Rent.


Commencing
November 1, 2015 and continuing through October 31, 2016, Lessee's Base Rent for Units #4
and #5 shall be $5,940. This rental rate takes into account the 1,000 square feet of Unit #4
that is associated with the common area pump house, and Lessee is not required to pay rent on said common area square footage.
On November 1, 2016, the Base Rent shall be adjusted, and on each anniversary date for the remainder of the Sublease term, by
any increase in the Consumer Price Index (for Ventura County, if available; otherwise for the Los Angeles/Long Beach metropolitan
area) that occurred over the preceding 12 month period (but not reduced)."


 



     


     


    




Lessor
and Lessee hereby consent to the foregoing Amendment of the Sublease. This Amendment does not release Lessee from liability for
any obligations of the Sublease under the Sublease.


  





 


	Dated: 6/4/15                            	Stellar Biotechnologies, Inc.
	 	 
	 	By: 	/s/ Frank Oakes
	 	 	Frank Oakes, CEO
Lessee



 


 


	Dated: 6/1/15                            	Port Hueneme Surplus Property Authority
	 	 
	 	By: 	/s/ Cynthia Haas
	 	 	 Cynthia Haas, Manager
Lessor
ADVISORY BOARD ON RADIATION AND WORKER HEALTH

4676 Columbia Parkway, MS: C-46 

Cincinnati, Ohio 45226

(513) 533-6825

CHAIRMAN

James M. Melius, M.D., Dr. PH.

 Albany, New York

MEMBERS

Henry Anderson, M.D.

 Madison, Wisconsin

Josie Beach

 Kennewick, Washington 

Bradley P. Clawson

 Rexburg, Idaho

R. William Field, Ph.D. 

 Iowa City, Iowa

Michael H. Gibson

 Franklin, Ohio

Mark A. Griffon

 Salem, New Hampshire

Richard Lemen, Ph.D.

 Canton, Georgia

James E. Lockey, M.D.

 Cincinnati, Ohio

Wanda I. Munn

 Richland, Washington

John W. Poston, Sr., Ph.D.

 College Station, Texas

Robert W. Presley

 Seymour, Tennessee

David B. Richardson, Ph.D.

Chapel Hill, North Carolina

Genevieve S. Roessler, Ph.D.

 Elysian, Minnesota

Phillip Schofield

 Bosque Farm, New Mexico

Paul L. Ziemer, Ph.D.

 Lafayette, Indiana

STAFF

EXECUTIVE SECRETARY

Theodore M. Katz, MPA

 Atlanta, Georgia

COMMITTEE MANAGEMENT 

Zaida Burgos

 Atlanta, Georgia

March 28, 2011

The Honorable Kathleen Sebelius

Secretary 

Department of Health and Human Services

200 Independence Avenue, S.W.

Washington, D.C. 20201

Dear Madam Secretary:

The Advisory Board on Radiation and Worker Health (The Board) has evaluated 

Special Exposure Cohort (SEC) Petition 00079 concerning employees who 

worked at the Dow Chemical Company site in Madison, Illinois, under the 

statutory requirements established by the Energy Employees Occupational 

Illness Compensation Program Act of 2000 (EEOICPA) and incorporated into 

42 CFR Sec. 83.13. The National Institute for Occupational Safety and Health 

(NIOSH) has recommended that individual dose reconstructions are feasible for 

workers at the Dow Chemical Company in Madison, Illinois, from January 1, 

1961 through November 30, 2007. 

NIOSH found that it has access to adequate exposure monitoring and other 

information necessary to do individual dose reconstructions with sufficient 

accuracy for members of this group, and therefore a class covering this group 

should not be added to the SEC. The Board concurs with this determination.

Enclosed is supporting documentation from the February 23-25, 2011 Board 

meeting held in Augusta, Georgia, and earlier meetings where this potential 

class for the SEC was discussed. If any of these items are unavailable at this 

time, they will follow shortly.

 Sincerely,

 [Signature on file]

James M. Melius, M.D., Dr. PH

Chairman, ABRWH

Enclosure
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5809 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
                                H. R. 5809

To amend title XVIII of the Social Security Act to encourage the use of 
 non-opioid analgesics for the management of post-surgical pain under 
             the Medicare program, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 15, 2018

Mr. Peters (for himself and Mr. Bucshon) introduced the following bill; 
  which was referred to the Committee on Energy and Commerce, and in 
    addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL

 
To amend title XVIII of the Social Security Act to encourage the use of 
 non-opioid analgesics for the management of post-surgical pain under 
             the Medicare program, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Postoperative Opioid Prevention Act 
of 2018''.

SEC. 2. MEDICARE INCENTIVES FOR USE OF NON-OPIOID ANALGESICS IN 
              HOSPITAL OUTPATIENT DEPARTMENTS AND AMBULATORY SURGICAL 
              CENTERS.

    Section 1833(t)(6) of the Social Security Act (42 U.S.C. 
1395l(t)(6)) is amended--
            (1) in subparagraph (C)(i), by inserting ``or, in the case 
        of an eligible non-opioid analgesic (as defined in subparagraph 
        (J)), during a period of 5 years,'' after ``3 years,''; and
            (2) by adding at the end the following new subparagraph:
                    ``(J) Eligible non-opioid analgesic defined.--In 
                this paragraph, the term `eligible non-opioid 
                analgesic' means a drug or biological--
                            ``(i) that is an analgesic that is not an 
                        opioid;
                            ``(ii) that demonstrated substantial 
                        clinical improvement; and
                            ``(iii) for which payment--
                                    ``(I) as an outpatient hospital 
                                service under this part was not being 
                                made as of the date of the enactment of 
                                this subparagraph; or
                                    ``(II) was being made under this 
                                paragraph as of such date.''.
                                 <all>
```
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Farm Credit Administration.

          - 12 CFR Part 620
          - RIN 3052-AC37

# AGENCY:

Farm Credit Administration.

# ACTION:

 Notice of effective date.

# SUMMARY:

                        The Farm Credit Administration (FCA) published a final rule under part 620 on December 4, 2007 (72 FR 68060). This final rule amends our regulations to allow Farm Credit System institutions 90 calendar days to prepare and distribute annual reports to shareholders while retaining the 75 calendar day requirement for electronic reporting and distribution to the FCA. In accordance with 12 U.S.C. 2252, the effective date of the final rule is 30 days from the date of publication in the                         **Federal Register**                         during which either or both Houses of Congress are in session. Based on the records of the sessions of Congress, the effective date of the regulations is February 6, 2008.                    

# DATES:

*Effective Date:*                         The regulation amending 12 CFR part 620 published on December 4, 2007 (72 FR 68060) is effective February 6, 2008.                    

# FOR FURTHER INFORMATION CONTACT:

Christopher D. Wilson, Policy Analyst, Office of Regulatory Policy, Farm Credit Administration, McLean, VA 22102-5090, (703) 883-4414, TTY (703) 883-4434; or Bob Taylor, Attorney Advisor, Office of General Counsel, Farm Credit Administration, McLean, VA 22102-5090, (703) 883-4020, TTY (703) 883-4020.

(12 U.S.C. 2252(a)(9) and (10))

Dated: February 6, 2008.

Roland E. Smith,

Secretary, Farm Credit Administration Board.

[FR Doc. 08-607  Filed 2-11-08; 8:45 am]

BILLING CODE 6705-01-M
Exhibit 32.1



CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the accompanying
report of Music of Your Life, Inc. (the “Company”) on Form 10-Q for the quarter ended August 31, 2016 (the “Report”),
I, Marc Angell, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | To my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------

Dated: October 24, 2016



|                       
|-----------------------
|                       
|/s/ Marc Angell        
|Marc Angell            
|Chief Executive Officer
[Federal Register Volume 73, Number 38 (Tuesday, February 26, 2008)]
[Notices]
[Page 10263]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-838]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Microbiology, Infectious Diseases and AIDS 
Initial Review Group; Acquired Immunodeficiency Syndrome Research 
Review Committee, AIDS Research Review Committee March 2008 Meeting.
    Date: March 25, 2008.
    Time: 9 a.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge 6700, 6700B 
Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).2 17 
CFR 240.19b-4.
    Contact Person: Erica L. Brown, PhD, Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, 
National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 
7616, Bethesda, MD 20892-7616, 301-451-2639, <a href="/cdn-cgi/l/email-protection#99fcfbebf6eef7d9f7f0f8f0fdb7f7f0f1b7fef6ef"><span class="__cf_email__" data-cfemail="a7c2c5d5c8d0c9e7c9cec6cec389c9cecf89c0c8d1">[email protected]</span></a>.


(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: February 19, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-838 Filed 2-25-08; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit






EXHIBIT 4.1


Termination of Registration Rights Agreement




Dated: December 4, 2015


Reference is made to that certain Registration Rights Agreement (the “Registration Rights Agreement”), dated as of June 9, 2015, by and among Ashford Hospitality Prime, Inc. (the “Company”), Ashford Hospitality Prime Limited Partnership (the “Operating Partnership”), Ashford Hospitality Advisors LLC (the “Advisor”) and MLV & Co. LLC (“MLV”) with respect to the Company’s 5.50% Series A Cumulative Convertible Preferred Stock (the “Series A Preferred Stock”). 


The Parties hereby terminate the Registration Rights Agreement, effective immediately, such that the Registration Rights Agreement shall be of no further force or effect, with no further liability of any party thereto.  




[THE REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]





















[Signature Page to Termination of Registration Rights Agreement]






IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date first above written.


	
			
	 
	ASHFORD  HOSPITALITY PRIME, INC.

	 
	 
	 

	 
	By:
	 /s/ David A. Brooks

	 
	 
	Name: David A. Brooks

	 
	 
	Title: Chief Operating Officer and General Counsel






	
			
	 
	ASHFORD HOSPITALITY PRIME LIMITED PARTNERSHIP

	 
	 
	 

	 
	By: Ashford Prime OP General Partner LLC, as the sole general partner

	 
	 
	 

	 
	By: Ashford Hospitality Prime, Inc., as the sole managing member        




    


	
			
	 
	By:
	 /s/ David A. Brooks

	 
	 
	Name: David A. Brooks

	 
	 
	Title: Vice President




	
			
	 
	ASHFORD HOSPITALITY ADVISORS LLC

	 
	 
	 

	 
	By:
	 /s/ David A. Brooks

	 
	 
	Name: David A. Brooks

	 
	 
	Title: Vice President




	
			
	 
	MLV & CO. LLC

	 
	 
	 

	 
	By:
	 /s/ Patrice McNicoll

	 
	 
	Name: Patrice McNicoll

	 
	 
	Title: CEO













[Signature Page to Termination of Registration Rights Agreement]
Fourth Court of Appeals

San Antonio, Texas

MEMORANDUM OPINION

No. 04-13-00546-CV

IN RE COCA-COLA REFRESHMENTS USA, INC., and Jon P. Rosales

Original Mandamus Proceeding1

PER CURIAM

Sitting: Sandee Bryan Marion, Justice

Rebeca C. Martinez, Justice

Patricia O. Alvarez, Justice

Delivered and Filed: August 21, 2013

PETITION FOR WRIT OF MANDAMUS DENIED

On August 12, 2013, relators Coca-Cola Refreshments USA, Inc. and Jon P. Rosales filed 

a petition for writ of mandamus and motion for temporary relief. The court has considered the 

petition for writ of mandamus and is of the opinion that relators are not entitled to the relief sought.

Accordingly, the petition for writ of mandamus and motion for temporary relief are denied. See 

TEX. R. APP. P. 52.8(a). 

PER CURIAM

1 This proceeding arises out of Cause No. 2012-CI-16160, styled Gerald J. Maurette v. Coca-Cola Refreshments USA, 

Inc. and Jon P. Rosales, pending in the 57th Judicial District Court, Bexar County, Texas, the Honorable Barbara 

Hanson Nellermoe presiding.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Homeland Security

###### U.S. Customs and Border Protection

# AGENCY:

U.S. Customs and Border Protection, Department of Homeland Security.

# ACTION:

Notice of accreditation and approval of Amspec Services LLC, as a commercial gauger and laboratory. 

# SUMMARY:

                        Notice is hereby given that, pursuant to 19 CFR 151.12 and 19 CFR 151.13, Amspec Services LLC, 1818 A Federal Road, Galena Park, TX 77015, has been approved to gauge and accredited to test petroleum and petroleum products, organic chemicals and vegetable oils for customs purposes, in accordance with the provisions of 19 CFR 151.12 and 19 CFR 151.13. Anyone wishing to employ this entity to conduct laboratory analyses and gauger services should request and receive written assurances from the entity that it is accredited or approved by the U.S. Customs and Border Protection to conduct the specific test or gauger service requested. Alternatively, inquiries regarding the specific test or gauger service this entity is accredited or approved to perform may be directed to the U.S. Customs and Border Protection by calling (202) 344-1060. The inquiry may also be sent to                         *cbp.labhq@dhs.gov*. Please reference the Web site listed below for a complete listing of CBP approved gaugers and accredited laboratories.                         *http://cbp.gov/​xp/​cgov/​import/​operations_​support/​labs_​scientific_​svcs/​commercial_​gaugers/​*.                    

# DATES:

The accreditation and approval of Amspec Services LLC, as commercial gauger and laboratory became effective on April 10, 2007. The next triennial inspection date will be scheduled for April 2010.

# FOR FURTHER INFORMATION CONTACT:

Commercial Gauger Laboratory Program Manager, Laboratories and Scientific Services, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202-344-1060.

Dated: January 31, 2008.

Ira S. Reese,

Executive Director, Laboratories and Scientific Services.

[FR Doc. 08-678 Filed 2-13-08; 8:45 am]

BILLING CODE 9111-14-M
Exhibit 32.1  CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  In  connection  with the  Quarterly  Report of Tripod  International,  Inc. (the "Company")  on Form 10-Q for the period  ended  December 31,  2008 as filed with the Securities  and  Exchange  Commission  on the date  hereof (the  "Report"),  the undersigned,  in the  capacities  and  on  the  dates  indicated  below,  hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:  1.   The Report fully  complies with the  requirements  of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  2.   The  information  contained  in the  Report  fairly  presents,  in all material respects,  the financial  condition and results of operations of the Company.  Date: February 10, 2009   /s/ Vera Vechera __________________________ Vera Vechera, President, Chief Executive Officer and Chief Financial Officer
| 1.   | The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and |
|----------------|--------------------------------------------------------------------------------------------------------------|

| 2.   | The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  By:    |  ___________________________________      |
|--------------|------------------------------------------------|
|  Name:  |  Zhijian James Zhang                      |
|  Title: |  Principal Executive Officer and Director |
|  Date:  |  November 12, 2010                        |

|  By:    |  ___________________________________      |
|--------------|------------------------------------------------|
|  Name:  |  Mandy Chung                              |
|  Title: |  Principal Financial Officer and Director |
|  Date:  |  November 12, 2010                        |
IIB 

115TH CONGRESS 

2D SESSION H. R. 5868 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 17, 2018 

Received; read twice and referred to the Committee on Homeland Security and 

Governmental Affairs 

AN ACT 

To designate the facility of the United States Postal Service 

located at 530 Claremont Avenue in Ashland, Ohio, as 

the ‘‘Bill Harris Post Office’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


pbinns on DSK79D2C42PROD with BILLS
2 

HR 5868 RFS

1 SECTION 1. BILL HARRIS POST OFFICE. 

2 (a) DESIGNATION.—The facility of the United States 

3 Postal Service located at 530 Claremont Avenue in Ash4 land, Ohio, shall be known and designated as the ‘‘Bill 

5 Harris Post Office’’. 

6 (b) REFERENCES.—Any reference in a law, map, reg7 ulation, document, paper, or other record of the United 

8 States to the facility referred to in subsection (a) shall 

9 be deemed to be a reference to the ‘‘Bill Harris Post Of10 fice’’. 

Passed the House of Representatives September 13, 

2018. 

Attest: KAREN L. HAAS, 

Clerk. 


pbinns on DSK79D2C42PROD with BILLS
**EXHIBIT23.1**

**CONSENT OFINDEPENDENT ACCOUNTANTS**

We hereby consent to the incorporation by reference inthe Registration Statements on Form F-3 (Nos. 333-109876,333-111512 and 333-119750), on Form S-3 (Nos. 333-128377,333-138872 and 323-139662) and on Form S-8 (Nos. 333-63580, 333-133258 and333-140041) of World Heart Corporation of our report dated March 29, 2007relating to the financial statements, which appear in this Annual Report onForm 10-KSB/A.

/s/PRICEWATERHOUSECOOPERS LLPOttawa, Canada April 27, 2007

----